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Introduction
Extracorporeal membrane oxygenation (ECMO) is a 
temporary artiﬁ cial extracorporeal support of the 
respiratory system and/or cardiac system used for the 
treatment of cardiopulmonary failure refractory to con-
ven tional therapies. More than 1,000 papers on ECMO 
published between January 2009 and May 2011 (PubMed 
search) clearly indicate a renewed interest in the tech-
nique, initially triggered by the CESAR trial publication 
[1] and the recent H1N1 ﬂ u pandemic. Indeed, during 
the pandemic the number of patients with acute 
respira tory distress syndrome (ARDS) who were not 
safely treatable with current clinical settings of mech-
anical ventilation (6 to 8 ml/kg tidal volume normalized 
on ideal body weight and plateau pressure lower than 30 
to 35 cmH2O) and who therefore received extracorporeal 
respiratory support appeared to be greatly increased. 
After providing a brief background and some technical 
notes, we will review the most important and recent 
ﬁ ndings related to the technique, its application and 
future applications.
Long-term ECMO, as support for severe respiratory 
failure, was ﬁ rst successfully used in 1972 in an adult 
patient with post-traumatic respiratory failure [2]. A few 
years later, at the University of California, Bartlett and 
colleagues successfully treated a newborn with ECMO 
[3]. Th e enthusiasm for this new technique led to a 
randomized trial sponsored by the National Institutes of 
Health that compared venous–arterial ECMO with 
conventional mechanical respiratory support in severe 
ARDS [4]. After randomization of 90 patients the trial 
was stopped for futility because the mortality in both 
groups was around 90%. However, one should note that 
the greatest concern for mechanical ventilation, at that 
time, was the high fraction of inspired oxygen and not 
the high ventilator pressure/volume; that is, nonphysio-
logical stress and strain. In this ECMO trial, therefore, 
the only diﬀ erence in mechanical ventilation settings 
between treatment and control patients was a lower FiO2
in the group that received the extracorporeal support. 
Moreover, the ECMO technology at these times was very 
primitive, with consistent risks for the patients due to 
high priming volumes of the extracorporeal circuits and 
elevated bleed ing risks associated with systemic anti-
coagulation. Th e limitations of this trial passed mostly 
unrecognized, however, and the discouraging results 
therefore led to the ECMO technique being abandoned 
worldwide.
During the same years, Kolobow was developing a new 
membrane lung optimized for carbon dioxide (CO2) 
removal as a possible application in patients with chronic 
obstructive pulmonary disease. While testing this new 
device in spontaneously breathing animals, however, we 
observed when part of the metabolically produced CO2
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was removed by the membrane lung that the ventilation 
of the animals proportionally decreased to maintain a 
constant blood partial pressure of CO2 [5]. Artiﬁ cial CO2 
removal could therefore be a powerful and valuable tool 
to control the respiratory drive up to complete apnea [6]. 
Indeed, the focus of extracorporeal support was shifted 
from oxygenation to CO2 removal, aiming to provide 
lung rest to allow better healing. Th e hypothesis of limit-
ing potential harmful stimuli was based uniquely on 
common sense, however, since concepts such as baby lung 
[7], atelectrauma [8], and so forth, were still unknown.
Th e ﬁ rst applications in humans of the concept of lung 
rest were reported in 1980 [9]. Soon after this experience 
a larger series of patients treated with extracorporeal CO2 
removal and low-frequency positive-pressure ventilation 
was described by the same authors [10]. However, a small 
randomized trial conducted in the United States at the 
beginning of the 1990s failed to show an outcome 
advantage of additional extracorporeal support as com-
pared with conventional mechanical ventilatory support 
[11]. Despite this lack of evidence, a few centers around 
Europe continued to provide veno-venous extracorporeal 
support in selected series of patients, usually as a last 
resort [12]. In contrast, in the United States Bartlett and 
colleagues continued to provide extracorporeal support 
with stan dard mechanical ventilation, with more liberal 
indica tions and with encouraging results [13,14].
A renewed interest in this technique arose after the 
publication of the CESAR trial, which clearly showed an 
improvement in the death rate and severe disability 
6 months after randomization, when patients with severe 
respiratory failure were treated with extracorporeal 
support in an expert high-case-volume center compared 
with nonspecialized hospital care [1]. Moreover, although 
not the primary outcome, an actual diﬀ erence in survival 
of around 25% was observed for patients considered for 
ECMO treatment at 28 days, the primary outcome of 
most ARDS literature. However, the ﬁ nal explosion of the 
application of this extracorporeal support was due to the 
use of ECMO as a rescue therapy in Australia and New 
Zealand during the H1N1 inﬂ uenza pandemic [15]. Th is 
increased use is also probably due to several technical 
improvements, which allowed a simpler and safer use of 
the technique. Among these innovations we can mention 
the introduc tion of nonporous hollow ﬁ ber devices, 
charac terized by low resistance to blood ﬂ ow, and poly-
methyl pentene ﬁ bers that, combined with nonthrombo-
genic coatings, decrease the need for platelet transfusion 
and continuous heparin infusion. Moreover, recently 
introduced wire-reinforced walls of vascular access 
devices allow very thin cannula walls, reducing resistance 
to blood ﬂ ow.
As the acronym ECMO includes several techniques 
with diﬀ erent aims, a brief reminder of the artiﬁ cial lung’s 
physiology is indicated to fully understand the diﬀ erent 
approaches, before discussing the latest reports on the 
topic.
Physiology of the artifi cial lung
Oxygenation
Th e amount of oxygen provided via artiﬁ cial lung is a 
direct function of the blood ﬂ ow. Th e blood ﬂ ow required 
during veno-venous bypass to achieve acceptable arterial 
oxygenation is usually between 3 and 6 l/minute, partially 
depending on the cardiac output of the patient, on the 
hemoglobin concentration and on saturation. Of note, 
the gas ﬂ ow required to fully oxygenate the incoming 
blood through the artiﬁ cial lung may be quite low. For 
example, if we consider an entering hemoglobin satura-
tion of 60% (with 3  l/minute extracorporeal blood ﬂ ow, 
10  g/dl hemoglobin concentration, 40  mmHg partial 
pressure of oxygen in venous blood and approximately 
85  ml/l oxygen content), to reach 100% saturation we 
would need 200 ml/minute oxygen. Providing 0.2 l/minute 
pure oxygen to a highly eﬃ  cient membrane lung would 
therefore theoretically be suﬃ  cient. Th is underlines the 
fact that what is of primary importance for artiﬁ cial 
oxygenation is the extracorporeal blood ﬂ ow passing 
through the membrane lung, and not its ventilation.
Th e eﬀ ects of the oxygen supplied by the membrane 
lung on systemic oxygenation depend on the type of 
cannulation and on the possible changes induced by the 
artiﬁ cial oxygenation on the function of the native lung. 
In a veno-venous circuit the artiﬁ cial lung is in series 
with the natural lung. Th e improvement in arterial 
oxygenation, in this case, is due to the increased oxygen 
saturation of the blood ﬂ owing through shunt regions of 
the natural lung. Great improvements from oxygenation 
can therefore not be expected. Moreover, with this type 
of vascular access, as blood with high oxygen saturation 
reaches the pulmonary artery, the shunt fraction of the 
natural lung usually increases due to the loss of hypoxic 
vasoconstriction [16]. Despite this, the veno-venous 
approach with high ﬂ ow, even with very high shunt in the 
natural lung, provides vital arterial oxygenation.
Th e veno-arterial approach, mostly used for cardiac 
support, implies the drainage of venous blood, its 
oxygenation and the subsequent input in the arterial tree 
through a cannulated artery. Th e improvement of 
systemic oxygenation with this technique is much better 
as compared with the veno-venous approach because the 
artiﬁ cially oxygenated blood mixes with arterial blood 
and directly perfuses distal organs. Moreover, in this type 
of cannulation – the artiﬁ cial lung being in parallel with 
the natural lung – there is no loss of hypoxic vaso-
constriction, because no highly oxygenated blood enters 
the pulmonary artery. Despite the unique ability to also 
provide cardiac support, this type of cannulation is 
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characterized by major disadvantages. First, an artery – 
typically the femoral artery – has to be cannulated with a 
large vascular catheter. Th is greatly increases the risk of 
ischemia of the inferior limb. Moreover, the aim of 
extracorporeal oxygenation (that is, to provide adequate 
oxygen supply to vital organs such as the brain and the 
heart) cannot be guaranteed through veno-arterial support 
if the input of oxygenated blood is performed distal to the 
great vessels; that is, through the femoral artery [16].
Carbon dioxide removal
Th e removal of CO2 is primarily a function of the ﬂ ow of 
fresh gas. Th eoretically it is possible to remove all of the 
metabolically produced CO2 (rate of elimination of CO2 
about 200 to 250  ml/minute) from 0.5 to 1  l/minute 
venous blood due to its high CO2 content (1 l of venous 
blood at partial pressure of CO2 45 mmHg and pH 7.38, 
in standard conditions, contains about 500  ml CO2). In 
this regard, the local acidiﬁ cation of entering blood may 
further enhance CO2 removal [17]. In the artiﬁ cial lung, 
therefore, while high extracorporeal blood ﬂ ow is 
required and low gas ﬂ ow is suﬃ  cient for oxygenation, 
for CO2 removal very low extracorporeal blood ﬂ ow is 
suﬃ  cient and high gas ﬂ ow is required.
Th e extracorporeal CO2 removal allows the lungs to be 
put to rest, abolishing totally or partially the need for 
ventilation [18]. Indeed, if the main purpose of the appli-
ca tion of the artiﬁ cial lung is to allow lung rest and a 
gentle ventilation of the baby lung, low extracorporeal 
blood ﬂ ows are suﬃ  cient [19]. In general, lower blood 
ﬂ ow is feasible with smaller endovascular catheters and is 
associated with lower technical diﬃ  culties and complica-
tions. Th e approach of arterio-venous bypass with a 
pumpless device allows consistent CO2 removal at the 
price of an arterio-venous ﬁ stula [20-22]. Low-ﬂ ow CO2 
removal systems coupled to or uncoupled from hemo-
ﬁ ltration may remove 20 to 30% of the rate of 
metabolically produced CO2 [23-26]. With artiﬁ cial lungs 
actually available, total CO2 clearance requires a blood 
ﬂ ow in the order of 1 to 2 l/minute. Moreover, it is con-
ceivable and desirable that, in the near future, regional 
anticoagulation (for example, with sodium citrate) will be 
available and will therefore greatly reduce the risk for 
bleeding due to systemic heparin infusion [27].
The H1N1 fl u pandemic
Th e rebirth of extracorporeal respiratory support is 
primarily due to its use as a rescue therapy for life-
threatening hypoxemia in Australia and New Zealand 
during the H1N1 ﬂ u pandemic [15]. Th e proper choice 
for such a purpose was therefore a veno-venous bypass 
with large-bore drainage catheters to allow high blood 
ﬂ ows. Th e overall survival rate in this selected population 
was higher than 70%. After this report and in light of 
results from the CESAR trial [1], an impressive number 
of centers started to use this technique despite some 
scientists having expressed some doubt on the scientiﬁ c 
evidence of its outcome advantages. Th e only evidence 
that led to the application of ECMO was the presence of 
moribund, severely hypoxemic patients that did not 
beneﬁ t from maximal mechanical ventilatory support 
[28-32]. Interestingly this technique was applied in 
Europe, the United States, South America, Canada and 
Asia, spreading as the H1N1 pandemic [33-38]. More 
than 1,000 papers were published from 2009 to May 
2011; however, most articles were not related to the use 
of ECMO in H1N1 ﬂ u but referred for other indications, 
such as lung hyperinﬂ ation, cardiac failure or severe 
respiratory failure not caused by H1N1.
Extracorporeal support is a tool to buy time, maintain-
ing life while awaiting improvement of the underlying 
disease. Th erefore, it is theoretically crucial to take 
advan tage of the extracorporeal support to minimize or, 
even better, to abolish the possible harm caused by an 
injurious mechanical ventilation. Extracorporeal CO2 
removal, in fact, partially or totally abolishes the need for 
ventilation, allowing one to apply a gentle ventilatory 
approach. It would therefore be interesting to know how 
mechanical ventilation was performed during extracor-
poreal support in the latest published studies. Surpris-
ingly, however, the details on settings of mechanical 
ventilators are diﬃ  cult to retrieve because when some 
mention of mechanical ventilation is made the infor ma-
tion is limited to a general agreement with ARDS Net-
work suggestions [39]. Some papers speciﬁ ed more 
details, which are still in line with lung-protective 
strategies aiming for a further reduction of tidal volume 
(for example, 3 to 5  ml/kg ideal body weight) while 
maintaining relative high mean airway pressure by high 
positive end-expiratory pressure (PEEP). In this scenario, 
however, we may ﬁ nd extreme diﬀ erences [15,36,40-42]. 
As an example, in several centers in Italy it was not 
uncommon to observe very low tidal volumes with the 
respiratory rate limited to 7 or 8  breaths/minute and a 
high mean airway pressure related to high PEEP 
application. On the other hand, in other units – for 
example at the Karolinska Institute of Stockholm – the 
patients are kept awake with 5  cmH2O PEEP and 
ventilated with pressure support of 20 to 25  cmH2O 
(personal communication, Dr Palmér, Section Manager 
of the ECMO Center, Karolinska Institute, Stockholm, 
Sweden). In our ICU in Milan, patients were treated 
initially with high PEEP, above 15  cmH2O, and low-
frequency ventilation [34]. To date, however, it is 
impossible to claim the superiority of a given treatment 
of the native lung during extracorporeal respiratory 
support as no studies are available on the topic. Th is lack 
of studies is primarily due to the scarcity of the patient 
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population. However, it is important to emphasize – at 
least with regard to H1N1 patients – that the survival 
rate ranged from 56 to 79% throughout the centers, inde-
pen dent of the applied strategy of mechanical ventilation 
[15,33,34,36].
We may therefore ask ourselves what we learned after 
this impressive utilization of extracorporeal support. 
First, extensive use of this technique all over the world in 
H1N1 patients conﬁ rmed that extracorporeal support is 
associated with high survival rates in severe hypoxemic 
patients. More over, we learned that these moribund 
patients may start time-buying extracorporeal respiratory 
support in the hospital of origin and thereafter be safely 
transferred to the referral ECMO centers. Th is practice 
has been clearly documented in Scandinavia [42,43] as 
well as in Italy [44].
Indications
Acute respiratory distress syndrome
After these considerations we may now discuss the actual 
indications for ECMO. Th e choice of the technique, which 
may vary from low-ﬂ ow bypass with CO2 removal to high-
ﬂ ow ECMO with total oxygenation support, depends on 
the patient’s situation and the physician’s preference.
Extracorporeal assistance as a rescue therapy
If the aim is the treatment of life-threatening hypoxemia, 
the clear-cut indication is high-ﬂ ow veno-venous ECMO. 
If the patient presents with severe cardiac failure, 
however, veno-arterial ECMO must be used. Th e obvious 
question is whether these types of treatment are asso-
ciated with a better outcome.
Th e recently published CESAR trial provided some 
clues in this regard [1]. Many physicians, however, were 
not fully convinced by the investigators’ approach [45-
47]. In fact, this pragmatic study really tested the 
diﬀ erences in outcome between a specialized center with 
high-volume activity and single centers with low-volume 
activity. Despite these limitations the study strongly 
indicated that treatment with extracorporeal support 
may increase the survival rate in a selected population of 
patients with ARDS. We may ask ourselves why, after 
over 30 years, a classical, adequately powered randomized 
trial has not been conducted in these severely hypoxemic 
patients. To test a possible mortality diﬀ erence of 10% 
between the ECMO and control arms would require 
enrollment of about 1,000 patients (with 90% power 
using a cutoﬀ  value for statistical signiﬁ cance of 0.05). 
Given that the enrollment rate of previous large 
randomized trials on severe ARDS [48-51] was 
approximately 0.3 patients/unit/month and that only 
one-third of these patients could have met the criteria for 
ECMO application – that is, severe refractory hypoxemia 
(partial pressure of oxygen <100  mmHg despite 100% 
FiO2) [52] – 20 ECMO centers would take over 40 years 
to complete the study (the CESAR trial took about 
8  years). It therefore seems to us that a classical 
randomized trial is not feasible.
Despite this, there seems a high likelihood that 
extracorporeal support has saved the lives of some 
extremely severe patients. ECMO seems to be indicated 
in this type of patient because the risks from compli-
cations of the technique seem irrelevant when almost 
certain death can be predicted. Th e question is diﬀ erent 
when severe hypoxemia is still manageable with more 
conventional approaches (high PEEP, high-frequency 
oscillatory ventilation, 100% FiO2, nitric oxide, and so 
forth). In these patients, the possible beneﬁ ts of extra cor-
poreal support have to be balanced with the only lethal 
complication of ECMO, which is intracranial hemor-
rhage. Unfortunately there are few data to predict with 
reasonable conﬁ dence the incidence of intracranial hemor-
rhage in adults [53]. According to the Italian ECMOnet 
experience, intracranial hemor rhage occurred in one 
patient out of 49 (personal com muni cation, Dr Patroniti, 
San Gerardo Hospital, Monza, Italy). In our experience, 
however, the incidence was about 5% and this compli-
cation occurred both in subjects treated for hematologic 
malignancy and in patients with no predictable cause of 
increased bleeding susceptibility. Any time we consider a 
patient for ECMO we must therefore keep in mind this 
unpredictable and lethal complication.
Extracorporeal assistance to provide lung rest
If the aim of applying the artiﬁ cial lung is not to assure 
oxygenation during hypoxemic emergency but to assure 
complete lung rest or to allow a protective lung strategy, 
CO2 removal is indicated. A technique that solely 
removes CO2 is applied in arterio-venous bypass [22]. 
With this technique the extra corporeal blood ﬂ ow is low 
and oxygen transfer negligible, the input blood in the 
oxygenator being arterial and therefore already highly 
saturated. In our opinion, however, in ARDS patients it is 
safe to remove CO2 using devices that also allow the 
performance of blood ﬂ ows up to 2 to 2.5  l/minute. In 
this way, if needed, not only may lung rest be provided 
but also oxygenation maintained, in case of natural lung 
function deterioration.
Extracorporeal assistance for indications other than ARDS
Increased conﬁ dence in using extracorporeal assistance 
led to use of the technique in diﬀ erent clinical conditions. 
Although outside the aim of the present review, the 
following conditions should be noted.
Bridge to lung transplant
Extracorporeal assistance has been successfully used as a 
bridge to lung transplant in patients with terminal 
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chronic obstructive pulmonary disease or cystic ﬁ brosis. 
Of note, there is an increased tendency to maintain those 
patients awake, and spontaneously breathing, without the 
need for intubation [54].
Lung hyperinfl ation
Lung hyperinﬂ ation is common during chronic obstruc-
tive pulmonary disease exacerbation or during status 
asthmaticus. In this condition, when noninvasive mech-
anical ventilation fails, extracorporeal support may be 
applied. Th e primary aim is to remove CO2, therefore 
reducing spontaneous ventilation and allowing progres-
sive lung deﬂ ation [55].
Cardiac failure
Th ere is much experience providing extracorporeal 
assistance during cardiogenic shock. In this condition the 
approach is obviously venous–arterial, providing not 
only respiratory but also cardiac assistance.
Conclusion
Recent events moved the spots of scientiﬁ c interest once 
again on extracorporeal techniques of respiratory support. 
Since the ﬁ rst experiences with ECMO, technology has 
hugely evolved, making extracorporeal respiratory support 
safer and more cost-eﬀ ective. Indeed, extracorporeal 
respiratory support is now an attractive strategy for the 
treatment of any type of respiratory failure in addition to, 
or even as an alternative to, mechanical ventilation.
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